

Elise Joelle Smolders

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/332484/elise-joelle-smolders-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19
papers

213
citations

8
h-index

14
g-index

19
ext. papers

274
ext. citations

3.5
avg, IF

3.43
L-index

#	Paper	IF	Citations
19	Meropenem to Treat Valproic Acid Intoxication.. <i>Therapeutic Drug Monitoring</i> , 2022 ,	3.2	1
18	Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. <i>Drugs in R and D</i> , 2021 , 21, 9-27	3.4	15
17	Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 288-298	2.9	1
16	Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patients. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2497-2506	3.8	11
15	SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection. <i>Antiviral Therapy</i> , 2020 , 25, 345-347	1.6	7
14	Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 231-243	6.1	23
13	An update on extravasation: basic knowledge for clinical pharmacists. <i>European Journal of Hospital Pharmacy</i> , 2020 ,	1.6	3
12	Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1237-1263	6.2	34
11	Increasing lithium concentration despite extracorporeal treatment: a case report. <i>Drugs and Therapy Perspectives</i> , 2019 , 35, 301-304	1.5	0
10	Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review. <i>Antiviral Therapy</i> , 2019 , 24, 529-540	1.6	4
9	Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring. <i>Journal of Hepatology</i> , 2019 , 70, 552-554	13.4	9
8	Cardiovascular Risk Management and Hepatitis C: Combining Drugs. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 565-592	6.2	12
7	The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report. <i>Annals of Hepatology</i> , 2018 , 17, 525-529	3.1	2
6	Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2225-2234	3.8	6
5	The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions. <i>United European Gastroenterology Journal</i> , 2017 , 5, 648-657	5.3	21
4	Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 76, 193-199	3.1	6
3	Measuring Plasma Concentrations of Ribavirin: First Report From a Quality Control Program. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 646-7	3.2	1

2	Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir. <i>Aids</i> , 2016 , 30, 1491-3	3.5	1
1	Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. <i>Drug Safety</i> , 2016 , 39, 589-611	5.1	56